← Eichor
Study identifier: NCT07246265 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care

Condition: Sickle Cell Disease · Glomerular Hyperfiltration · Sickle Cell Nephropathy  ·  Sponsor: University Hospital, Tours

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal. Thus, red blood cells can be blocked in small vessels, responsible for painful crises due to a lack of downstream circulation. These crisis (acute vaso-occlusive crisis) require strong treatment based on morphine, and often require intensive care.However, treatment is often insufficiently effective. Patient can also experiment acute chest syndrome, a complication of vaso-occlusive crisis, which can be responsible for respiratory failure. In addition, patients with sickle cell disease frequently have kidney damage called sickle cell nephropathy, which in the early stages of the disease is responsible for renal hyperfiltration, meaning that the kidneys filter the blood more than necessary, with faster elimination of drugs. For example, it is known that higher doses of antibiotics must be used in these patients than in the general population for the same effectiveness. The hypothesis of the study is that morphine, a drug eliminated by kidneys, is underdosed in patients with sickle cell disease, which is responsible for the difficulties in achieving sufficient analgesia. Objective: To determine the glomerular filtration rate threshold for which it is necessary to prescribe higher doses of morphine in sickle cell patients with vaso-occlusive crisis. Methods: inclusion of 100 patients admitted to intensive …

This description comes directly from the study's public registry record.

Talk to the study team

Charlotte SALMON-GANDONNIERE, MD  ·  +33 2 47 47 38 55  ·  charlotte.salmon.gandonniere@gmail.com

Coralie TAILLEBUIS  ·  +332 47 47 39 09  ·  cpcq@chu-tours.fr

Always discuss trial participation with your own doctor first.

Locations (6)

CHRU de ToursTours, France, FranceRecruiting
Henri-MondorCréteil, FranceNot Yet Recruiting
CH Le MansLe Mans, FranceNot Yet Recruiting
CHU de NantesNantes, FranceNot Yet Recruiting
CHU d'OrléansOrléans, FranceNot Yet Recruiting
CHU de RennesRennes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07246265